- Home
- SINT vs KPRX Comparison
SINT vs KPRX Comparison
Compare SINT & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SINT
- KPRX
- Stock Information
- Founded
- SINT 1996
- KPRX 1998
- Country
- SINT United States
- KPRX United States
- Employees
- SINT N/A
- KPRX N/A
- Industry
- SINT Medical/Dental Instruments
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SINT Health Care
- KPRX Health Care
- Exchange
- SINT Nasdaq
- KPRX Nasdaq
- Market Cap
- SINT 7.9M
- KPRX 9.1M
- IPO Year
- SINT 2014
- KPRX N/A
- Fundamental
- Price
- SINT $3.20
- KPRX $2.90
- Analyst Decision
- SINT Strong Buy
- KPRX Strong Buy
- Analyst Count
- SINT 1
- KPRX 1
- Target Price
- SINT $28.00
- KPRX $10.00
- AVG Volume (30 Days)
- SINT 55.8K
- KPRX 1.3M
- Earning Date
- SINT 08-12-2025
- KPRX 08-08-2025
- Dividend Yield
- SINT N/A
- KPRX N/A
- EPS Growth
- SINT N/A
- KPRX N/A
- EPS
- SINT N/A
- KPRX N/A
- Revenue
- SINT $2,569,000.00
- KPRX $20,000.00
- Revenue This Year
- SINT $3.26
- KPRX N/A
- Revenue Next Year
- SINT $21.87
- KPRX N/A
- P/E Ratio
- SINT N/A
- KPRX N/A
- Revenue Growth
- SINT N/A
- KPRX N/A
- 52 Week Low
- SINT $1.71
- KPRX $2.51
- 52 Week High
- SINT $8.60
- KPRX $4.86
- Technical
- Relative Strength Index (RSI)
- SINT 54.73
- KPRX 43.33
- Support Level
- SINT $3.05
- KPRX $2.87
- Resistance Level
- SINT $3.38
- KPRX $3.22
- Average True Range (ATR)
- SINT 0.23
- KPRX 0.18
- MACD
- SINT -0.00
- KPRX -0.02
- Stochastic Oscillator
- SINT 45.12
- KPRX 5.77
About SINT SiNtx Technologies Inc.
SINTX Technologies Inc is a ceramics company, focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. It has grown from focusing on the research, development, and commercialization of medical devices manufactured with silicon nitride to becoming a renowed ceramics company engaged in diverse fields, including biomedical, technical, and antipathogenic applications. Its biomedical products are biocompatible, bioactive, antipathogenic, and to have good bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans in the US, Europe, Brazil, and Taiwan.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.